Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96HN2

UPID:
SAHH3_HUMAN

ALTERNATIVE NAMES:
IP(3)Rs binding protein released with IP(3) 2; Long-IRBIT; S-adenosyl-L-homocysteine hydrolase 3; S-adenosylhomocysteine hydrolase-like protein 2

ALTERNATIVE UPACC:
Q96HN2; B4DIZ5; D9N155; O94917

BACKGROUND:
The protein Adenosylhomocysteinase 3, with alternative names such as Long-IRBIT and S-adenosylhomocysteine hydrolase-like protein 2, is implicated in the regulation of the electrogenic sodium/bicarbonate cotransporter SLC4A4 and its magnesium sensitivity. This regulation is critical for maintaining cellular ion balance, distinguishing it from its homolog AHCYL1 by not influencing ITPR1's response to inositol 1,4,5-trisphosphate.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Adenosylhomocysteinase 3 offers a promising pathway for identifying novel therapeutic interventions. Its involvement in key cellular regulatory mechanisms makes it a potential target for developing drugs aimed at correcting dysregulated ion transport and metabolic processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.